Merge Healthcare – FDA Warning Letter, Apr 23, 2012

On April 16-23, 2012, an FDA inspection of Merge Healthcare's Winchester, Tennessee facility, which manufactures Blood Pressure Monitoring Computer Kiosks, revealed significant violations of the Quality System (QS) regulation (21 CFR Part 820), rendering their devices adulterated under Section 501(h) of the Federal Food, Drug, and Cosmetic Act.

Key violations include: 1. **CAPA Procedures (21 CFR 820.100(a)):** Failure to establish adequate CAPA procedures, specifically lacking a defined process for analyzing quality data and initiating CAPAs based on such analysis. The firm's response was inadequate, failing to provide details on process definition, procedure updates, or retrospective data analysis plans. 2. **Complaint Handling (21 CFR 820.198(a)):** Inadequate procedures for receiving, reviewing, and evaluating complaints. The complaint handling procedure (SOP047) did not define what constitutes a complaint or actions for non-injury related malfunctions. Multiple malfunctions were documented as service reports but not as formal complaints. The firm's response lacked details on CAPA implementation or systemic corrective action. 3. **Complaint Investigation (21 CFR 820.198(c)):** Failure to investigate complaints involving possible device failure. Numerous device failures were noted without documented investigations or reference to prior investigations